La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Ligand Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Ligand Pharmaceuticals' Il CEO è Todd Davis, nominato in Dec2022, e ha un mandato di 1.67 anni. la retribuzione annua totale è $ 6.22M, composta da 10.5% di stipendio e 89.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.43% delle azioni della società, per un valore di $ 8.10M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 14.8 anni.

Informazioni chiave

Todd Davis

Amministratore delegato

US$6.2m

Compenso totale

Percentuale dello stipendio del CEO	10.5%
Mandato del CEO	1.7yrs
Proprietà del CEO	0.4%
Durata media del management	1.8yrs
Durata media del Consiglio di amministrazione	14.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Todd Davis rispetto agli utili di Ligand Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$42m
Mar 31 2024	n/a	n/a	US$96m
Dec 31 2023	US$6m	US$650k	US$54m
Sep 30 2023	n/a	n/a	US$21m
Jun 30 2023	n/a	n/a	US$41m
Mar 31 2023	n/a	n/a	US$51m
Dec 31 2022	US$6m	US$49k	-US$5m
Sep 30 2022	n/a	n/a	US$23m
Jun 30 2022	n/a	n/a	US$27m
Mar 31 2022	n/a	n/a	US$45m
Dec 31 2021	US$328k	n/a	US$76m
Sep 30 2021	n/a	n/a	US$68m
Jun 30 2021	n/a	n/a	US$48m
Mar 31 2021	n/a	n/a	US$39m
Dec 31 2020	US$329k	n/a	US$7m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$25m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$350k	n/a	US$629m
Sep 30 2019	n/a	n/a	US$594m
Jun 30 2019	n/a	n/a	US$677m
Mar 31 2019	n/a	n/a	US$764m
Dec 31 2018	US$343k	n/a	US$143m
Sep 30 2018	n/a	n/a	US$179m
Jun 30 2018	n/a	n/a	US$120m
Mar 31 2018	n/a	n/a	US$53m
Dec 31 2017	US$283k	n/a	US$13m

Compensazione vs Mercato: La retribuzione totale di Todd ($USD 6.22M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.62M ).

Compensazione vs guadagni: La retribuzione di Todd è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Todd Davis (63 yo)

1.7yrs

Mandato

US$6,216,518

Compensazione

Mr. Todd C. Davis, Ph.D. is Director at NVN Liquidation Inc. He serves as an Independent Director of Chromocell Therapeutics Corporation since January 2023 and its Chairman of the Board. He is Chief Execut...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Todd Davis	CEO & Director	1.7yrs	US$6.22m	0.43% $ 8.2m
Matthew Korenberg	President & COO	1.8yrs	US$3.59m	0.37% $ 7.1m
Octavio Espinoza	Chief Financial Officer	1.8yrs	US$2.45m	0.13% $ 2.4m
Andrew Reardon	Chief Legal Officer & Secretary	1.8yrs	US$2.34m	0.12% $ 2.3m
Paul Hadden	Senior Vice President of Investments & Business Development	no data	Nessun dato	Nessun dato
Michael Jeong	Head of Investor Relations	no data	Nessun dato	Nessun dato
Todd Pettingill	Director of Corporate Development	no data	Nessun dato	Nessun dato
Keith Marschke	Senior Vice President of Biology & Scientific Affairs	6.6yrs	Nessun dato	Nessun dato
Vincent Antle	Senior Vice President of Technical Operations & QA - Capitsol	6.6yrs	Nessun dato	Nessun dato
Patrick Lucy	Senior VP & CBO Protein Expression Business	no data	Nessun dato	Nessun dato
Karen Reeves	Senior VP of Investments & Head of Clinical Strategy	less than a year	Nessun dato	Nessun dato
Richard Baxter	Senior VP of Investment Operation	less than a year	Nessun dato	Nessun dato

1.8yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di LGND non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Todd Davis	CEO & Director	17.4yrs	US$6.22m	0.43% $ 8.2m
John Kozarich	Independent Chairman	21.4yrs	US$361.70k	0.23% $ 4.4m
John LaMattina	Independent Director	13.5yrs	US$329.20k	0.15% $ 2.9m
Stephen Sabba	Independent Director	16yrs	US$341.70k	0.16% $ 3.0m
Jason Aryeh	Independent Director	17.9yrs	US$339.20k	0.45% $ 8.5m
Shalendar Bhasin	Scientific Advisor	no data	Nessun dato	Nessun dato
Jason Haas	Independent Director	2.2yrs	US$346.70k	0.023% $ 429.4k
Nancy Gray	Independent Director	7yrs	US$336.70k	0.031% $ 583.5k
Martine Zimmermann	Independent Director	less than a year	US$467.87k	Nessun dato

14.8yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di LGND è composto da personale esperto e esperto (durata media dell'incarico 14.8 anni).

Ligand Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Financial Officer notifies of intention to sell stock

President & COO recently sold US$1.5m worth of stock

Chief Legal Officer & Secretary notifies of intention to sell stock

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024

CEO & Director exercised options to buy US$1.2m worth of stock.

Chief Financial Officer notifies of intention to sell stock

Recent updates

Ligand Pharmaceuticals Incorporated Reaffirms Financial Guidance for the Full Year of 2024

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Ligand Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 06, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into an agreement to acquire APEIRON Biologics AG for $128 million.

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Chief Financial Officer notifies of intention to sell stock

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

President & COO recently sold US$1.5m worth of stock

Consensus EPS estimates increase by 199%

Chief Legal Officer & Secretary notifies of intention to sell stock

First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

CEO & Director exercised options to buy US$1.2m worth of stock.

Chief Financial Officer notifies of intention to sell stock

Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Announces Management Appointments

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 28%, revenue upgraded

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

CEO & Director recently bought US$238k worth of stock

Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors

Ligand Pharmaceuticals Incorporated Reaffirms Revenue Guidance for 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) announces an Equity Buyback for $50 million worth of its shares.

Ligand's Collaborator Merck Announces V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Ligand Pharmaceuticals Incorporated to Report Q2, 2023 Results on Aug 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $15 million.

Consensus EPS estimates increase by 73%

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Independent Chairman recently sold US$343k worth of stock

Independent Chairman notifies of intention to sell stock

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

Ligand Pharmaceuticals Incorporated Raises Earnings Guidance for 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 41%

Full year 2022 earnings released: US$0.31 loss per share (vs US$3.44 profit in FY 2021)

Ligand Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 22, 2023

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Executive Director notifies of intention to sell stock

Executive Director exercised options to buy US$998k worth of stock.

Ligand Pharmaceuticals Incorporated Announces CEO Changes

Price target decreased to US$111

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%

Insufficient new directors

Chief Financial Officer recently sold US$128k worth of stock

Price target decreased to US$131

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022

Insufficient new directors

Ligand Pharmaceuticals Incorporated Appoints Octavio (Tavo) Espinoza as Chief Financial Officer

Ligand Pharmaceuticals Incorporated to Report Q3, 2022 Results on Nov 07, 2022

Price target decreased to US$149

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt